RCM
KRYS icon

RA Capital Management’s Krystal Biotech KRYS Stock Holding History

RA Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-496,071
Closed -$5M – 29
2018
Q1 		$5M Sell
496,071
-203,929
-29% -$2.01M 0.38% 26
2017
Q4 		$7.36M Hold
700,000
– – 0.62% 22
2017
Q3 		$6.98M Buy
+700,000
New +$7.06M 0.63% 23

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RA Capital Management's KRYS Position: Q2 2018 in Review

RA Capital Management sold out of Krystal Biotech (KRYS) in Q2 2018, closing a stake of 496,071 shares — an estimated $5M sold.

RA Capital Management first reported a position in KRYS in Q3 2017 and held it in 3 quarters. The position peaked at $7.36M in Q4 2017. 17 funds tracked by Wall St. Rank hold KRYS as of Q2 2018.

  • RA Capital Management reported no remaining Krystal Biotech position as of Q2 2018 after selling out during the quarter.
  • RA Capital Management sold 496,071 Krystal Biotech shares in Q2 2018, an estimated $5M.
  • RA Capital Management first reported a position in Krystal Biotech in Q3 2017 and held it in 3 quarters.
  • RA Capital Management's Krystal Biotech position peaked at $7.36M in Q4 2017.
  • 17 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2018.

Based on RA Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.